CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Bio-Rad Laboratories’ Geenius HIV-1/HIV-2 Supplemental Assay, which received premarket application approval from the FDA, can differentiate circulating antibodies to HIV types 1 and 2 in whole blood, serum, and plasma. The assay offers a three-step procedure that produces onscreen results in 30 minutes with full traceability. The Geenius Reader can then analyze and interpret reaction results for HIV-1 (p31 HIV-1 polymerase peptide, gp160 HIV-1 recombinant protein envelope, p24 HIV-1 recombinant protein core, and gp41 Group M and O HIV-1 peptide envelope) and HIV-2 (gp 36 and gp 140 HIV-2 peptide envelope).
Key benefits, according to the company, include minimal training, qualitative interpretation, and a user-friendly graphic interface.
Bio-Rad, 510-724-7000